Form 4: Zevra Therapeutics Director Granted 30,000 Stock Options as Board Compensation

Corey Michael Watton, a Director at Zevra Therapeutics, Inc., was granted 30,000 stock options with an exercise price of $8.62 as part of his compensation for board service.

Summary

• Corey Michael Watton, a Director of Zevra Therapeutics, Inc. (ZVRA), was granted 30,000 stock options on May 29, 2025.
• The options have an exercise price of $8.62 per share, which is equal to the closing price of ZVRA's common stock on the Nasdaq Global Select Market on the grant date.
• This grant was awarded as compensation for Mr. Watton's service on the Issuer's board of directors, in accordance with the company's tenth amended and restated non-employee director compensation policy.
• The options will vest 100% on the earliest of: the first anniversary of the grant date, the date that is one day prior to the first annual stockholders meeting occurring after the grant date, or immediately prior to a change in control of the Issuer, subject to Mr. Watton's continued service.
• The options are exercisable immediately upon grant and expire on May 28, 2035.
• Following this transaction, Mr. Watton directly beneficially owns 30,000 derivative securities.

Sentiment

Score: 7

Explanation: The document reports a standard compensation event for a director, indicating normal corporate governance and compensation practices. It is a neutral to slightly positive event as it aligns director interests with shareholders, but does not convey significant new operational or financial news that would drastically alter sentiment.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value creation of Zevra Therapeutics.
• The compensation is formalized under the Issuer's tenth amended and restated non-employee director compensation policy, indicating structured corporate governance.

Future Outlook

The vesting schedule for the stock options indicates a future alignment of the director's incentives with the company's performance over the next year or until a change in control, contingent on continued service, reinforcing long-term commitment.

Management Comments

• "The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, May 29, 2025."
• "This grant was awarded as compensation for the Reporting Person's service on the Issuer's board of directors pursuant to the Issuer's tenth amended and restated non-employee director compensation policy."
• "One hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the first anniversary of the date of grant, (ii) the date that is one day prior to the first annual stockholders meeting occurring after the grant date or (iii) immediately prior to a change in control of the Issuer, subject in each case to the Reporting Person's continued service on such vesting date."

Industry Context

This transaction is a routine insider filing, common in the biotechnology and pharmaceutical industries, where equity compensation is a standard practice to attract and retain experienced board members and align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options as compensation for non-employee directors is a standard practice across various industries, including biotechnology and pharmaceuticals.
• The vesting schedule, which includes time-based vesting (first anniversary or prior to annual meeting) and acceleration upon a change of control, is typical for such equity awards.
• This compensation structure is comparable to practices at other publicly traded biotech companies like BioNTech, Moderna, or Gilead Sciences, which frequently utilize similar equity incentives for their board members to ensure alignment with shareholder value.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholder value creation, as the options gain value if the stock price increases, potentially leading to more focused governance.

Next Steps

• Continued service of Corey Michael Watton on the Zevra Therapeutics board of directors.
• Vesting of the 30,000 stock options based on the specified conditions (first anniversary of grant, day prior to first annual stockholders meeting, or change in control).

Key Dates

Recommendation

Keywords

Zevra Therapeutics, ZVRA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corey Michael Watton